Idiopathic Pulmonary Fibrosis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Global Blood Therapeutics Drops Idiopathic Pulmonary Fibrosis, But Sickle Cell Disease Is At The Forefront - Seeking Alpha



Seeking Alpha
 
Global Blood Therapeutics Drops Idiopathic Pulmonary Fibrosis, But Sickle Cell Disease Is At The Forefront 
Seeking Alpha
On Monday, Global Blood Therapeutics (GBT) announced that it would discontinue its idiopathic pulmonary fibrosis program. The main reason for discontinuing the program was that no clinically meaningful results were achieved in any of the trials done.
Global Blood Therapeutics to terminate studies of idiopathic pulmonary fibrosis program Pharmaceutical Business Review
Global Blood Therapeutics Ceases GBT440 Research Program for IPF Pulmonary Fibrosis News
Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program GlobeNewswire (press release)
MarketWatch  -STAT  -FierceBiotech  -Zacks.com 
all 107 news articles » 


Many IPF Patients in Europe Not Given Approved Treatments, Survey Finds - Pulmonary Fibrosis News



Pulmonary Fibrosis News
 
Many IPF Patients in Europe Not Given Approved Treatments, Survey Finds 
Pulmonary Fibrosis News
Despite the availability of approved antifibrotic treatments for idiopathic pulmonary fibrosis (IPF), many patients in Europe do not receive them, partly due to a lack of awareness by physicians or a preference for a ?wait and watch? approach in people ...

 


Idiopathic Pulmonary Fibrosis Market - Global Opportunity Analysis and Industry Forecast, 2017-2023 - PR Newswire (press release)



Idiopathic Pulmonary Fibrosis Market - Global Opportunity Analysis and Industry Forecast, 2017-2023 
PR Newswire (press release)
LONDON, Nov. 2, 2017 /PRNewswire/ -- Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023.

and more » 


Idiopathic Pulmonary Fibrosis Pipeline Overview 2017 Market Insights and Epidemiology - Medgadget (blog)



Idiopathic Pulmonary Fibrosis Pipeline Overview 2017 Market Insights and Epidemiology 
Medgadget (blog)
RnRMarketResearch.com announces a new report ?Idiopathic Pulmonary Fibrosis Pipeline Insights, 2017? added to its Pharmaceuticals business research collection of its growing online library. ?Idiopathic Pulmonary Fibrosis ? Pipeline Insights, 2017 ...

 


OFEV Slows Progression of Fibrosis, Lung Imaging in Phase 3b Trial Shows - Pulmonary Fibrosis News



Pulmonary Fibrosis News
 
OFEV Slows Progression of Fibrosis, Lung Imaging in Phase 3b Trial Shows 
Pulmonary Fibrosis News
Researchers presented the Phase 3b trial results at the Pulmonary Fibrosis Foundation Summit 2017 in Nashville, Nov. 9-11. It was titled ?Effect of nintedanib on disease progression: results from a Phase IIIb trial in patients with idiopathic pulmonary ...

and more » 


PF Foundation Summit Highlights Roles of Care, Research, and Technology - Lung Disease News



Lung Disease News
 
PF Foundation Summit Highlights Roles of Care, Research, and Technology 
Lung Disease News
One poster won the ?winning presentation? title, and its presenter, Taylor Adams of Yale University, School of Medicine, talked about his single cell RNA-sequencing project in idiopathic pulmonary fibrosis (IPF). Another highlight was the debate about ...

and more » 


Esbriet Reduces Cough in Patients with Idiopathic Pulmonary Fibrosis, Dutch Study Shows - Pulmonary Fibrosis News



Pulmonary Fibrosis News
 
Esbriet Reduces Cough in Patients with Idiopathic Pulmonary Fibrosis, Dutch Study Shows 
Pulmonary Fibrosis News
Treatment with Esbriet (pirfenidone) reduces cough in patients with idiopathic pulmonary fibrosis (IPF), a new European study finds. The study, ?Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis,? appeared in the European ...

 


Molecular pathway offers treatment targets for pulmonary fibrosis, related conditions - Medical Xpress



Medical Xpress
 
Molecular pathway offers treatment targets for pulmonary fibrosis, related conditions 
Medical Xpress
A chest radiograph of a patient with Idiopathic Pulmonary Fibrosis (IPF). Credit: Wikipedia/CC BY-SA 3.0. A study led by investigators at Massachusetts General Hospital (MGH) and University Health Network (UHN) in Toronto has identified a molecular ...

and more » 


Idiopathic Pulmonary Fibrosis ? Pipeline Review, H2 - MilTech



Idiopathic Pulmonary Fibrosis ? Pipeline Review, H2 
MilTech
Idiopathic Pulmonary Fibrosis Market report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of ...

and more » 


Prometic Receives Fast Track Designation for PBI-4050 in Development for Idiopathic Pulmonary Fibrosis (IPF) - Canada NewsWire (press release)



Prometic Receives Fast Track Designation for PBI-4050 in Development for Idiopathic Pulmonary Fibrosis (IPF) 
Canada NewsWire (press release)
LAVAL, QC, Oct. 25, 2017 /CNW/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBI-4050, a clinical candidate in development for ...

and more »